Skip to main content

Table 1 Clinical characteristics

From: Decreased methylation in the SNAI2 and ADAM23 genes associated with de-differentiation and haematogenous dissemination in breast cancers

Variables n %
All   59 100.0
Age ≤50 13 22.0
  > 50 46 78.0
Histology DIC 49 83.1
  Others 10 16.9
Tumour size (mm) ≤20 34 57.6
  > 20 25 42.4
LNM statusa 0 17 28.8
  ≥1 42 71.2
TNM classification I 14 23.7
  II 22 37.3
  III 23 39.0
Grade 1 and 2 36 63.2
  3 21 36.8
Hormone receptor statusb Negative 8 13.6
  Positive 51 86.4
HER2 statusc Normal 16 27.1
  Amplified 43 72.9
Ki-67 proliferative indexd Low 35 59.3
  High 24 40.7
Tumour multifocality Negative 51 87.9
  Positive 7 12.1
CTC anye Negative 30 50.8
  Positive 29 49.2
CTC epithelial Negative 45 76.3
  Positivef 14 23.7
CTC mesenchymal Negative 40 67.8
  Positiveg 19 32.2
CTCe and LNM status Negat. / Posit. 29 50.0
  Posit. / Negat. 16 27.6
  Posit. / Posit. 13 22.4
  1. Abbreviations: DIC ductal invasive carcinoma, LNM lymph node metastasis, HER2 human epidermal growth factor receptor 2, CTC circulating tumour cell
  2. aLNM status was categorized according to the number of metastatic LNs
  3. bNegative for both (oestrogen receptor and progesterone receptor) or positive for either with cut-off 10%
  4. cHER2 status was determined immunohistochemically according to ASCO guidelines [53]
  5. dCut-off 20%
  6. eCTCs were detected through the quantification of EMT-inducing transcription factor gene transcripts
  7. fOut of them 4 BC patients had simultaneously mesenchymal CTC
  8. gOut of them 4 BC patients had simultaneously epithelial CTC